Latest total revenue for CLVS: $130M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2022
Trailing 12 months ending Sep 2022
Clovis Oncology (CLVS) currently reports a total revenue of $130M as of September 2022. That compares with $160M in the prior-year period — down 14.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Clovis Oncology's total revenue history and peer comparisons.
Clovis Oncology's total revenue decreased from $160M to $130M — a 14.8% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Clovis Oncology's total revenue of $130M is lower than the Healthcare sector average of $110B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Clovis Oncology reported $130M in total revenue as of September 2022. That compares with $160M in the prior-year period — down 14.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Clovis Oncology, and consider following CLVS for alerts when major investors trade the stock.